Advancements in the field of cellular immunotherapy have accelerated in recent years and
have changed the treatment landscape for a variety of hematologic malignancies. Cellular …

Immunotherapy has changed treatment practices for many hematologic malignancies. Even
in the current era of targeted therapy, chemotherapy remains the backbone of treatment for …

Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and
CAR-natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation …

Despite the introduction of a plethora of different anti-neoplastic approaches including
standard chemotherapy, molecularly targeted small-molecule inhibitors, monoclonal …

Recently, the use of chimeric antigen receptor-modified T (CAR-T)-cells in the treatment of
hematological tumors has been successful and has become a clinical hotspot in tumor …

Over the past few years, cellular immunotherapy has emerged as a novel treatment option
for certain forms of hematologic malignancies with multiple CAR-T therapies now routinely …

The development of chimeric antigen receptor T (CAR-T) cell therapy, a specific type of
immunotherapy, in recent decades was a fantastic breakthrough for the treatment of …

The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products
in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However …

Simple Summary In recent years, innovative immunotherapy-based treatments have paved
the way for a new approach to hematological malignancies. Instead of conventional …

Advancements in adoptive cell therapy over the last four decades have revealed various
new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated …